TherapeuticsMD, Inc. (TXMD) AI Stock Analysis

TherapeuticsMD, Inc. is a women's healthcare company based in Boca Raton, Florida, focused on treatments for women's health needs across the United States. Its commercial portfolio includes IMVEXXY for moderate-to-severe dyspareunia associated with menopause, BIJUVA for vasomotor symptoms, and ANNOVERA, a long-acting contraceptive vaginal system. The company also produces prescription prenatal vitamins under brands such as vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1. In addition, TherapeuticsMD is developing preclinical pipeline candidates including TX-005HR, TX-006HR, TX-007HR, TX-008HR, and TX-009HR across transdermal and oral hormone therapies.

TherapeuticsMD experienced significant volatility over the past five fiscal years, posting a 5-year revenue CAGR of -45.8% from FY2020 to FY2025. After revenue fell 98.1% to $1.3M in FY2023, revenue rose 35.3% to $1.8M in FY2024 and 71.6% to $3.0M in FY2025. Net income was -$569,000 with diluted EPS of $0.07 in FY2025, improving from a net loss of -$2.2M in FY2024. Gross margin reached 100.0% in FY2023, FY2024, and FY2025, while operating margin improved from -275.1% to -139.4%. For the trailing twelve months ended June 30, 2026, revenue stood at $3.3M, though the latest quarter saw revenue decline 8.7% and quarterly earnings decline 80.6% year-over-year.

As of June 30, 2026, TherapeuticsMD held $9.2M in cash and short-term investments against total debt of $5.6M, resulting in net cash of $3.6M. The company maintains a current ratio of 3.22 and a debt-to-equity ratio of 0.20 against shareholders' equity of $27.1M and total assets of $37.5M. Operating cash flow and free cash flow both reached $2.4M in FY2025, up from $732,000 in FY2024. Over the past 5 years, the company's share count expanded by 36.2%.

TherapeuticsMD trades at a forward P/E of 2.3x, compared to the median of 17.3x for its US-listed Healthcare peers. Its enterprise value stands at $21.4M with an EV-to-EBITDA multiple of 14.8x, above the peer median of 12.0x, while its price-to-sales ratio of 6.7x exceeds the peer median of 4.1x. Over the past year, the stock returned 81.0%, outperforming the S&P 500 return of 16.8%. However, its 5-year return of -94.7% trails the S&P 500 return of 83.0%.

Wall Street coverage provides a mean price target of $5.00 for TherapeuticsMD, representing a 163.2% premium over its last close of $1.90 on October 16, 2026. The company has surpassed EPS estimates in 1 of the trailing 4 quarters. Institutional investors hold 31.7% of the equity, while insider ownership stands at 9.0%, and short interest accounts for 0.3% of the float. TherapeuticsMD has its next earnings announcement scheduled for November 11, 2026.

This page is an AI-written research summary of TherapeuticsMD, Inc. (TXMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TXMD income statement, TXMD balance sheet, TXMD key metrics, TXMD chart. See the TXMD stock overview for the latest quote and news.